ArticleClinical genitourinary cancer2019
Racial and Ethnic Disparities in Renal Cell Carcinoma: An Analysis of Clinical Characteristics.
Article in Clinical genitourinary cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Racial and ethnic disparities in the cause of death for clear cell renal cell carcinoma.Nature communications · 2026Article
- Review
- Trends in mortality among patients with malignant neoplasm of kidney in the United States, 1999-2023: a retrospective study.BMC cancer · 2026Article
- Mortality trends of malignant neoplasm of kidney among 5-85+ year-olds in the United States: a retrospective analysis.Frontiers in oncology · 2026Article
- Isoechoic Renal Tumors: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Concurrent Renal Cell Carcinoma Diagnosis in a Married Couple: Risk Factors and Unmet Survivorship Needs.Cureus · 2025Article
- Examining the evolving landscape of kidney cancer mortality in the United States.The oncologist · 2025Article
- Evaluating Patient Adherence and Persistence to Tyrosine-Kinase Inhibitors for Metastatic Renal Cell Carcinoma: A Retrospective Analysis of Real-World Data.Clinical Medicine Insights. Oncology · 2025Article
- The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care.BJUI compass · 2024Review
- Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma.The oncologist · 2023Article
- Recent Advances in the Management of Clear Cell Renal Cell Carcinoma: Novel Biomarkers and Targeted Therapies.Cancers · 2023Review
- Clear cell renal cell carcinoma molecular variations in non-Hispanic White and Hispanic patients.Cancer medicine · 2023Article
- Differences in incidence, staging, and survival of urologic cancers in patients under 65 living in the US-Mexico border region.Current urology · 2023Article
- Heart Metastases of Clear Cell Renal Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2023Article
- Renal Cell Carcinoma Surgical Treatment Disparities in American Indian/Alaska Natives and Hispanic Americans in Arizona.International journal of environmental research and public health · 2022Article
- Comparing Age at Cancer Diagnosis between Hispanics and Non-Hispanic Whites in the United States.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Racial and Ethnic Disparities in Preoperative Surgical Wait Time and Renal Cell Carcinoma Tumor Characteristics.Healthcare (Basel, Switzerland) · 2021Article
- Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research.Journal of the National Cancer Institute · 2021Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundRacial/ethnic minority groups, including Hispanic Americans (HAs) and Native Americans (NAs), have a heavier burden of kidney cancer than European Americans (EAs). We investigated variations in clinical characteristics of HA and NA patients with renal cell carcinoma (RCC) who were previously underrepresented. MATERIALS AND
methodsClinical records of 294 patients with RCC (151 EAs, 95 HAs, 22 NAs, and 26 others) without prior diagnosis of cancer were reviewed. Logistic regression analysis was performed to understand patients' clinical characteristics.
resultsHAs had about 5 years younger average age at diagnosis than EAs (55.8 vs. 60.5 years) and an almost 3-fold increased odds of diagnosis before age 50 years (odds ratio [OR], 2.77; 95% confidence interval [CI], 1.39-5.54). The mean age of diagnosis among NAs was 49.7 years, and NAs had an over 6-fold higher odds of diagnosis at a younger age (OR, 6.23; 95% CI, 2.00-19.46). Clear-cell RCC (ccRCC) was more common in HAs and NAs than EAs. Over 90% of HA patients had ccRCC, whereas only 78.8% of EA patients had ccRCC. HAs had increased odds of diagnosis with ccRCC compared with EAs (OR, 2.79; 95% CI, 1.15-6.80). Among HAs, older patients and patients who spoke Spanish as their primary language were more likely to have advanced stage RCC at diagnosis (OR, 10.48; 95% CI, 1.69-64.89 and OR, 4.61; 95% CI, 1.38-15.40).
conclusionHA and NA patients with RCC had different clinical characteristics than EA patients. It is necessary to better understand the clinical characteristics of these underserved HA and NA populations with high kidney cancer burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.